No Data
No Data
Roche Launches Tender Offer for Poseida Therapeutics
Roche Commences Tender Offer for All Shares of Poseida Therapeutics, Inc. for $9.00 per Share in Cash, Plus a Non-tradeable Contingent Value Right for up to $4.00 per Share in Cash
Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Piper Sandler Maintains Poseida Therapeutics(PSTX.US) With Hold Rating, Maintains Target Price $10
No Data